Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KHHDG
ADC Name
huMy9-6IgG1-Compound (la) DAR3.9
Synonyms
huMy9 6IgG1 Compound (la) DAR3.9
   Click to Show/Hide
Organization
Orum Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
Drug-to-Antibody Ratio
3.9
Structure
Antibody Name
huMy9-6 IgG1
  Antibody Info 
Antigen Name
Myeloid cell surface antigen CD33 (CD33)
  Antigen Info 
Payload Name
NeoDegrader P1
  Payload Info 
Therapeutic Target
Protein cereblon (CRBN)
  Target Info 
Linker Name
huMy9-6IgG1-Compound (la) DAR3.9 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
9.9
pM
HL-60 cells
Adult acute myeloid leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 9.90 pM Positive CD20 expression (CD20+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
References
Ref 1 Neodegrader conjugates; 2021-10-07.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.